Humacyte Forecast, price target & analysts
Humacyte Target price 2025 - Analyst rating & recommendation
Humacyte Classifications & Recommendation:
Humacyte Price Target
| Target Price | $5.36 |
| Price | $1.47 |
| Potential |
264.29%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Humacyte 2026 .
The average Humacyte target price is $5.36.
This is
264.29%
register free of charge
$26.25
1,685.71%
register free of charge
$3.03
106.12%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Humacyte to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Humacyte stock has an average upside potential 2026 of
264.29%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 6.54 |
8 Analysts have issued a sales forecast Humacyte 2025 . The average Humacyte sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Humacyte EBITDA forecast 2025. The average Humacyte EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $-107m | 16.14% |
|---|---|---|
| 2025 |
$-60.5m
43.37%
Unlock
|
|
EBITDA Margin
8 Humacyte Analysts have issued a net profit forecast 2025. The average Humacyte net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.26 | -0.25 |
| 17.76% | 80.16% | |
| P/E | negative | |
| EV/Sales | 32.40 |
8 Analysts have issued a Humacyte forecast for earnings per share. The average Humacyte EPS is
This results in the following potential growth metrics and future valuations:
Current Humacyte Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Aug 27 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 11 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jul 23 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jul 09 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jun 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 27 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 11 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jul 23 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jul 09 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jun 09 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
